Sparks, NV -- November 29, 2017 -- InvestorsHub NewsWire -- RESTANCE, Inc. (USOTC: ANCE) recently announced winning a contract to manufacture Playboy brand name condoms for distribution in in Africa, starting in Kenya as part of a the #DoIt4Africa buy-one-give-one campaign where an anticipated $20 million in condoms will be sold in North American and for every condom sold, a condom will be manufactured in Africa and given away in Africa.  The contract was announced in conjunction with World AIDS Day which takes place tomorrow, December 1, 2017.  RESTANCE is participating in the #DoIt4Africa campaign to contribute to the United Nations goal of ending the AIDS Epidemic.
 
Hefner and Playboy Ahead Of Their Time In Fighting AIDS and Advocating Gay Rights
 
In conjunction with World AIDS Day, RESTANCE is paying tribute to Hugh Hefner and Playboy’s role in the fight against AIDS and support of Gay Rights.  Hefner and Playboy are on record as early as 1955 in support of Gay Rights.  When AIDS was being dismissed as a “gay plague,” Playboy discussed it as a wider concern and advocated for safer sex.  Hefner said, “The only thing “wrong” with AIDS is the way our government responded to it. They are culpable on many, many levels.”
 
Learn more about Playboy and Hefner’s role in fightin AIDS in Advocating for Gay Rights in the recent article:
 
This is what Playboy founder Hugh Hefner thought about AIDS and gay rights
 
 
In addition to opening a condom manufacturing plant, RESTANCE is pursuing several other business lines in the growing economies of East Africa. The Company is developing opportunities in the region including initiatives in technology and systems integration services, utility support services, affordable housing and health products manufacturing. RESTANCE recently acquired East African Development Partners as part of its strategy in East Africa.
 
Learn more about the RESTANCE operations in Africa on the Company's website: www.restanceinc.com
 
Other OTC quoted companies with services addressing the AIDS epidemic include DanDrit Biotech (DDRT), Immune Therapeutics (IMUN) and Progressive Care (RXMD).

Disclaimer/Safe Harbor:
 
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.
 
Randell Torno
ir@restanceinc.com 
+1-800-834-5792
 

Restance (CE) (USOTC:ANCE)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024 Haga Click aquí para más Gráficas Restance (CE).
Restance (CE) (USOTC:ANCE)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024 Haga Click aquí para más Gráficas Restance (CE).